Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ignace Vergote

Showing results (491-500 of 578) with videos related to

Pageof 58
Sort By:
European Journal of Cancer (Oxford, England : 1990)|February 26, 2025
Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized studyIgnace Vergote, Larry J Copeland, Toon Van Gorp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2023
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial CancerIgnace Vergote, Jose Alejandro Pérez-Fidalgo, Erika Paige Hamilton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2020
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary PeritoneumBradley J Monk, Rachel N Grisham, Susana Banerjee, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trialDomenica Lorusso, Marie-Ange Mouret-Reynier, Philipp Harter, et al.
Gynecologic Oncology|June 4, 2024
Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO studyVicky Makker, Jose Alejandro Perez-Fidalgo, Giorgio Valabrega, et al.
The New England Journal of Medicine|September 29, 2019
Niraparib in Patients with Newly Diagnosed Advanced Ovarian CancerAntonio González-Martín, Bhavana Pothuri, Ignace Vergote, et al.
The Lancet. Oncology|February 10, 2019
Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicentre, prospective, cohort studyWouter Froyman, Chiara Landolfo, Bavo De Cock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2018
Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell CarcinomaJoseph J Caumanns, Katrien Berns, G Bea A Wisman, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 21, 2023
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trialDomenica Lorusso, Marie-Ange Mouret-Reynier, Philipp Harter, et al.
Journal of the National Cancer Institute|April 25, 2026
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25)Florence Joly, Amélie Anota, Sylvie Chabaud, et al.
Pageof 58

Showing results (491-500 of 578) with videos related to

Sort By:
Pageof 58
European Journal of Cancer (Oxford, England : 1990)|February 26, 2025
Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized studyIgnace Vergote, Larry J Copeland, Toon Van Gorp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2023
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial CancerIgnace Vergote, Jose Alejandro Pérez-Fidalgo, Erika Paige Hamilton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2020
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary PeritoneumBradley J Monk, Rachel N Grisham, Susana Banerjee, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trialDomenica Lorusso, Marie-Ange Mouret-Reynier, Philipp Harter, et al.
Gynecologic Oncology|June 4, 2024
Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO studyVicky Makker, Jose Alejandro Perez-Fidalgo, Giorgio Valabrega, et al.
The New England Journal of Medicine|September 29, 2019
Niraparib in Patients with Newly Diagnosed Advanced Ovarian CancerAntonio González-Martín, Bhavana Pothuri, Ignace Vergote, et al.
The Lancet. Oncology|February 10, 2019
Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicentre, prospective, cohort studyWouter Froyman, Chiara Landolfo, Bavo De Cock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2018
Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell CarcinomaJoseph J Caumanns, Katrien Berns, G Bea A Wisman, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 21, 2023
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trialDomenica Lorusso, Marie-Ange Mouret-Reynier, Philipp Harter, et al.
Journal of the National Cancer Institute|April 25, 2026
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25)Florence Joly, Amélie Anota, Sylvie Chabaud, et al.
Pageof 58